Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy

European Journal of Internal Medicine

Volumn 19, Issue 2, 2008, Pages 122-128

  Medeiros, Marta Maria C ^a   Menezes, Ana Paula T ^b   Silveira, Virgínia Angélica ^b   Ferreira, Fernanda Nogueira H ^b   Lima, George Rafael ^a   Ciconelli, Rozana Mesquita ^c  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Hospital Universitario Walter Cantidio   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclophosphamide pulse therapy; Health related quality of life; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; BRAZIL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BRAZIL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PULSE THERAPY, DRUG; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 38749113334     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.06.012     Document Type: Article

References (37)

1. Gilboe I.M., Kvien T.K., and Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol 26 (1999) 1694-1700
2. Perez-Cuevas J.B., Formiga F., Garcia-Carraco M., Ramos M., Lara C., and Rojas-Rodriguez J. A quality of life study in women with systemic lupus erythematosus and its relation to disease activity. An Med Interna 16 9 (1999) 457-460
3. Sutcliffe N., Clarke A.E., Levinton C., Frost C., Gordon C., and Isenberg D.A. Associates of health status in patients with SLE. J Rheumatol 26 (1999) 2352-2356
4. Alarcón G.S., McGwin G., Uribe A., et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 51 3 (2004) 465-474
5. Doria A., Rinaldi S., Ermani M., et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology 43 12 (2004) 1580-1586
6. Gladman D.D., Urowitz M.B., Ong A., Gough J., and MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 14 3 (1996) 305-308
7. Stoll T., Gordon C., Seifert B., et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 24 (1997) 1608-1614
8. Saba J., Quinet R.J., Davis W.E., et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Jt Bone Spine 70 5 (2003) 348-351
9. Rupert N., Buratti S., Duarte-Salazar C., et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthrtitis Rheum 51 3 (2004) 458-464
10. Greco C.M., Rudy T.E., and Manzi S. Effects of disease activity, pain, and distress on activity limitations in patients with systemic lupus erythematosus. J Rheumatol 31 2 (2004) 260-267
11. Jolly M., and Utset T.O. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?. Lupus 13 12 (2004) 924-926
12. Appel G.B., Cohen D.J., Pirani C.L., Meltzer J.I., and Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 83 (1987) 877-885
13. Gourley M.F., Austin H.A., and Scott D. Methylprednisolone and cyclophosphamide alone or in combination in patients with lupus nephritis. A randomized controlled trial. An Intern Med 125 7 (1996) 549-557
14. Dooley M.A., and Falk R.J. Immunosuppressive therapy of lupus nephritis. Lupus 7 (1998) 630-634
15. Takada K., Illei G.O., and Boumpas D.J. Cyclophosphamide for the treatment of lupus erythematosus systemic. Lupus 10 3 (2001) 154-161
16. Fraenkel L., Bogardus S., and Concato J. Patients preferences for treatment of lupus nephritis. Arthritis Rheum 47 4 (2002) 421-428
17. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
18. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 9 (1997) 1725
19. Urowitz M.B., Gladman D.D., Tozman E.C., and Goldsmith C.H. The Lupus Activity Criteria Count (LACC). J Rheumatol 11 6 (1984) 783-787
20. Ciconelli R.M., Ferraz M.B., Santos W., Meinão I., and Quaresma M.R. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36. Rev Bras Reumatol 39 3 (1999) 143-150
21. Gladman D.D., Urowitz M.B., Ong A., Gough J., and MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus. Lupus 5 3 (1996) 190-195
22. Ware J.E., Kosinski M., and Keller S.D. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute. New England Medical Centre (1994)
23. Ware J., Kosinski M., Bayliss M., Rogers W.H., and Raczec A. Comparison of methods for the scoring and statistical analysis of SF-36 Health Profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33 4 (1995) AS264-AS279
24. Mari J.J., and Williams P. A comparison of the validity of two psychiatric screening questionnaires (GHQ-12 and SRQ-20) in Brazil, using relative operating characteristic (ROC) analysis. Psychol Med 15 3 (1985) 651-659
25. StataCorp Stata Statistical Software: release 7.0. Stata Corporation, 2001.
26. Gladman D., Urowitz M., Fortin P., et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in Systemic Lupus Erythematosus. Systemic Lupus International Collaborating Clinics Group. J Rheumatol 23 (1996) 1953-1955
27. Freire E.A., Maia I.O., Nepomuceno J.C.A., and Ciconelli R.M. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheum 26 (2007) 423-428
28. Ferraz M.B. Avaliação da qualidade de vida em pacientes com Lupus Eritematoso com manifestações cutâneas (2001), UNIFESP (Tese), São Paulo
29. Meinão I.M. Utilização de Recursos e Custos em pacientes com Lupus Eritematoso Sistêmico (2001), UNIFESP (Tese), São Paulo
30. D ́Amorim A.B. Avaliação das formas auto-administrativas dos questionários MHAQ e SF-12 em pacientes com doenças reumatológicas (2001), UNIFESP (Tese), São Paulo
31. Vu T.V., and Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J Rheumatol 26 (1999) 2595-2601
32. Wang C., Mayo N.E., and Fortin P.R. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 28 (2001) 525-532
33. Bae S.C., Hashimoto H., Karlson E.W., Liang M.H., and Daltroy L.H. Variable effects of social support by race, economic status, and disease activity in systemic lupus erythematosus. J Rheumatol 28 (2001) 1245-1251
34. Karlson E.W., Daltroy L.H., Lew R.A., et al. The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 40 (1997) 47-56
35. Panopalis P., Petri M., Manzi S., et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology 44 (2005) 751-755
36. Rood M.J., Borggreve S.E., and Huizinga T.W. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol 27 8 (2000) 2057-2059
37. Fortin P.R., Abrahamowicz M., Neville C., et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 7 (1998) 101-107